People with mild Alzheimer’s disease who received plasma exchange with albumin replacement showed improvement in memory, language abilities, processing speed, and quality of life, AMBAR trial data showed. (Alzheimer’s & Dementia)
Fewer people treated with erenumab (Aimovig) for migraine prevention stopped taking the drug due to adverse events compared with those treated with topiramate (Topamax) in the phase IV HER-MES trial. (Cephalalgia)
Biogen said it is reviewing adverse events possibly linked to its Alzheimer’s drug aducanumab (Aduhelm), “including the fatal case of a 75-year-old patient whose cause of death remains under investigation and who was diagnosed during hospitalization with cerebral edema thought to be ARIA-E.” (Endpoints News)
Higher frequency of fish intake was associated with lower MRI cerebrovascular disease burden in older adults, especially among people younger than 75. (Neurology)
The Tau NextGen trial, originally slated to focus on treatment targeting tau among people with dominantly inherited Alzheimer’s disease, will include an arm that evaluates two drugs targeting amyloid and tau at the same time. (Washington University School of Medicine)
Distal sensory polyneuropathy in people with HIV was linked to increased activity in the anterior insula, which is involved in predicting pain. (Brain Communications)
Amylyx Pharmaceuticals submitted a new drug application to the FDA for AMX0035 (sodium phenylbutyrate and taurursodiol), its investigational ALS treatment.
Sharif Tabebordbar, PhD, sought to cure his father’s facioscapulohumeral muscular dystrophy. He may not be able to do that, but his breakthrough gene therapy work may help others. (New York Times)
The FDA approved liquid topiramate (Eprontia) for seizures associated with epilepsy and for migraine prevention, Azurity Pharmaceuticals announced.
A reproductive history that signaled more estrogen exposure was linked with larger gray matter volume in midlife women. (Neurology)
Source: MedicalNewsToday.com
